What is the evidence base for Gonadorelin (GnRH)?

Gonadorelin (GnRH)'s evidence base sits at established. The references on this page summarise 2 primary publications supporting the principal mechanism and applications. Where Phase II or Phase III human data exists for related indications, it is cited; where evidence is preclinical or limited to small case series, that is noted. The protocol / scheduling / cycling interpretation respects the actual evidence tier rather than over-stating mechanistic plausibility.

How does Gonadorelin (GnRH)'s half-life affect dosing?

Gonadorelin (GnRH) has a plasma half-life of ~2-4 min, which is short enough to require multiple daily doses to maintain therapeutic exposure. The receptor occupancy curve under every other day, mimicking pulsatile release dosing at 50-200 mcg per dose explains the typical onset timeline for scheduling and cycle endpoints.

What is the standard dosing protocol for Gonadorelin (GnRH)?

Conventional Gonadorelin (GnRH) dosing is 50-200 mcg every other day, mimicking pulsatile release via subq. For scheduling and cycle use specifically, the cycle pattern is typically 8–12 weeks on followed by a 4 week off-period. Higher doses are studied in advanced protocols but produce diminishing dose-response in the published literature.

What does Gonadorelin (GnRH) stack well with?

For protocol / scheduling / cycling protocols, Gonadorelin (GnRH) pairs with compounds on complementary pathways: BPC-157, TB-500, Ipamorelin. These pairings are selected because they engage independent receptor systems from Gonadorelin (GnRH)'s primary mechanism (Binds the GnRH receptor on anterior pituitary gonadotrophs in a pulsatile fashion to stimulate LH (and to a lesser extent FSH) release), producing additive or synergistic effects rather than receptor competition.

What route should I use for Gonadorelin (GnRH)?

Gonadorelin (GnRH) is delivered by subq. Subcutaneous administration is standard for ${o.cat.toLowerCase()} class peptides and provides reliable systemic bioavailability. The choice depends on target system and convenience.

What class of compound is Gonadorelin (GnRH)?

Gonadorelin (GnRH) is classified as a Hypothalamic decapeptide. Within this class, alternative names and analogues include Gonadotropin-releasing hormone, LHRH. The class-level pharmacology shapes both the clinical applications and the safety profile; the protocol / scheduling / cycling literature treats Gonadorelin (GnRH) alongside its class peers when evaluating relative merits.

Home/ Compounds/ Gonadorelin (GnRH)

Gonadorelin (GnRH)

Protocol

Scheduling Gonadorelin (GnRH) alongside existing protocols, training, and lifestyle inputs requires understanding the compound's pharmacokinetic constraints and the cycle calendar. The natural decapeptide that drives pituitary release of LH and FSH — used clinically and increasingly as an HCG alternative during testosterone therapy. Daily timing relative to meals and training, weekly cycle structure, and integration with stack components on independent pathways are the three layers of the protocol calendar developed below.

Protocol / Scheduling / Cycling Applications

Off-TimeProtocol CalendarStack SchedulingMaintenance PhaseLoading Phase

Key Takeaways

Scheduling lens: Gonadorelin (GnRH)'s ~2-4 min half-life via subq places it in the multi-daily-dosing bucket.
Mechanism: Binds the GnRH receptor on anterior pituitary gonadotrophs in a pulsatile fashion to stimulate LH (and to a lesser extent FSH) release.
Cycle structure: 8-12 weeks on, 4 weeks off; the off-period is functionally required for receptor reset.
Stack scheduling: add one compound at a time with 2 weeks of isolated dosing before layering.
Schedule-compatible stack partners: BPC-157, TB-500, Ipamorelin.

Protocol / Scheduling / Cycling Mechanism

Binds the GnRH receptor on anterior pituitary gonadotrophs in a pulsatile fashion to stimulate LH (and to a lesser extent FSH) release. The pulsatile pattern is critical: continuous exposure desensitises and downregulates the receptor (the basis of GnRH-agonist chemical castration drugs). Schedule design for Gonadorelin (GnRH) starts from the pharmacokinetic constraints implied by this mechanism and the published half-life. The subsections below address daily and weekly timing, cycle length and off-period planning, stack scheduling with other compounds, and travel-and-continuity considerations.

Cycle length and off-cycle planning

Standard Gonadorelin (GnRH) cycle length is 8–12 weeks for most users, with off-cycle periods of 4–6 weeks calibrated to allow receptor sensitivity to recover and any cumulative downregulation to resolve. The off-cycle is not optional in well-designed protocols; it is the period during which the dose response is reset for the next cycle.

Travel, schedule shifts, and continuity

Maintaining cycle continuity through travel, time-zone shifts, and irregular schedules is one of the practical considerations for any Gonadorelin (GnRH) protocol. Cold-chain requirements (where applicable), customs considerations for international travel, and adjustment for time-zone shifts within a 24–48 hour window are the main operational issues. For most Gonadorelin (GnRH) schedules a ±8-hour timing shift has no clinical effect; longer shifts warrant minor schedule adjustment.

Daily and weekly timing

Gonadorelin (GnRH) with a ~2-4 min half-life pharmacokinetic profile sits in the daily-dosing bucket. The schedule is best built around either Every other day, mimicking pulsatile release, with consistency mattering more than the absolute clock time of any single dose.

Protocol / Scheduling / Cycling Applications

Off-Time

The most-asked scheduling question for Gonadorelin (GnRH) in off-time is when to time doses relative to meals and training. The general principle: fasted dosing for compounds engaging the GH axis or AMPK; meal-paired dosing for incretins; flexibility for compounds whose pharmacokinetics permit it.

Periodised Cycles

Schedule design for Gonadorelin (GnRH) in periodised cycles starts from pharmacokinetic constraints: less frequent dosing for long half-life compounds. The cycle length and off-period are then layered on top of the daily schedule.

Tapered Cycles

For tapered cycles scheduling, Gonadorelin (GnRH) is best run in 8–12 week cycles with 4 week off-periods. Daily timing within the cycle is calibrated to pharmacokinetics; weekly timing is calibrated to training and lifestyle constraints. The schedule is the protocol.

Maintenance Phase

The most-asked scheduling question for Gonadorelin (GnRH) in maintenance phase is when to time doses relative to meals and training. The general principle: fasted dosing for compounds engaging the GH axis or AMPK; meal-paired dosing for incretins; flexibility for compounds whose pharmacokinetics permit it.

Dosing Protocol

Goal	Route	Dose	Cycle
Standard protocol	SubQ	50-200 mcg	8–12 weeks on / 4 weeks off
Conservative starter	SubQ	30-200 mcg	4–6 weeks initial cycle
Protocol focus	SubQ	50-200 mcg	Every other day, mimicking pulsatile release
Maintenance phase	SubQ	35-200 mcg	Ongoing with periodic pauses

Dose timing for Gonadorelin (GnRH) is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.

Stacking

Gonadorelin (GnRH) stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from protocol designers.

Gonadorelin (GnRH) + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with Gonadorelin (GnRH)'s mechanism in protocol / scheduling / cycling protocols.
Gonadorelin (GnRH) + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with Gonadorelin (GnRH)'s mechanism in protocol / scheduling / cycling protocols.
Gonadorelin (GnRH) + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with Gonadorelin (GnRH)'s mechanism in protocol / scheduling / cycling protocols.
Gonadorelin (GnRH) + CJC-1295 without DAC (Mod GRF 1-29): Same GHRH-receptor agonism as DAC variant. Pairs naturally with Gonadorelin (GnRH)'s mechanism in protocol / scheduling / cycling protocols.

Safety & Regulatory Status

WADA: Not on prohibited list for males in non-IH context FDA: Approved for diagnostic LH/FSH testing Research: Established

Generally well tolerated. Headache and injection site reactions occasional. Continuous (non-pulsatile) administration causes paradoxical suppression — dose timing matters.

Lens-specific safety considerations for protocol / scheduling / cycling use of Gonadorelin (GnRH): Generally well tolerated. Headache and injection site reactions occasional. Continuous (non-pulsatile) administration causes paradoxical suppression — dose timing matters. Additional protocol / scheduling / cycling monitoring at baseline and 6–8 week follow-up is appropriate.

Clinical Evidence

Primary

GnRH pulsatility and gonadotrope function

PMID 26282249

Supporting

Gonadorelin in hypogonadotropic conditions

PMID 11122438

Gonadorelin (GnRH) vs Related Peptides

Compound	Profile	Onset	Best For
Gonadorelin (GnRH)	Hypothalamic decapeptide	~2-4 min	Protocol
BPC-157	Stable gastric pentadecapeptide	~4 hr (oral)	Accelerated tendon, ligament, and gut tissue repair via VEGFR2-driven angiogenesis and FAK-paxillin signalling
TB-500	Synthetic thymosin β4 fragment	~2-3 days	A 17-amino-acid synthetic fragment of thymosin β4 with actin-sequestering activity — drives cell migration, tissue repair, and broad regenerative effects
Ipamorelin	Selective GHRP / ghrelin mimetic	~2 hr	The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite
GHK-Cu	Tripeptide-copper complex	~30 min plasma	A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression

Frequently Asked Questions

Can I shift my schedule with travel?

Up to ±8 hours of timing shift has no clinical effect for most peptide schedules. Time-zone changes longer than 8 hours warrant a minor schedule adjustment over 1–2 days to re-anchor the cycle. Cold-chain requirements during travel are the more important operational concern.

What if I miss a dose?

Single missed doses are not consequential for most peptide schedules. Resume the next scheduled dose; do not double-dose. Multiple consecutive missed doses (3+) effectively start an off-period and warrant re-evaluating cycle progress before resuming.

Daily timing for Gonadorelin (GnRH)?

Pragmatic timing depends on pharmacokinetics: multi-daily dosing for short half-life. Consistent timing matters more than the absolute clock time of any single dose.

Best practice for re-cycling?

Run baseline labs before each cycle. Compare to prior cycle. Adjust dose downward if response is maintained; adjust upward only if response is incomplete and labs support the safety margin. Long-term cycle records inform protocol drift over years.

What is Gonadorelin (GnRH)?

Gonadorelin (GnRH) (also known as Gonadotropin-releasing hormone / LHRH) is a 10-residue hypothalamic decapeptide with a molecular weight of 1182 Da and a plasma half-life of ~2-4 min. Binds the GnRH receptor on anterior pituitary gonadotrophs in a pulsatile fashion to stimulate LH (and to a lesser extent FSH) release. The pulsatile pattern is critical: continuous exposure desensitises and downregulates the receptor (the basis of GnRH-agonist chemical castration drugs). The compound is studied primarily in the protocol / scheduling / cycling domain for the applications outlined above.

What is the mechanism of action of Gonadorelin (GnRH)?

Binds the GnRH receptor on anterior pituitary gonadotrophs in a pulsatile fashion to stimulate LH (and to a lesser extent FSH) release. The pulsatile pattern is critical: continuous exposure desensitises and downregulates the receptor (the basis of GnRH-agonist chemical castration drugs). For scheduling and cycle applications specifically, the relevant downstream consequence is the cascade from receptor engagement to systemic effect: Binds the GnRH receptor on anterior pituitary gonadotrophs in a pulsatile fashion to stimulate LH (and to a lesser extent FSH) release. The protocol / scheduling / cycling interpretation focuses on the pathway-level detail rather than on any single high-level summary.

Clinical Protocol

Start a Gonadorelin (GnRH) Protocol

Alukard provides physician-supervised peptide protocols with GMP-certified Gonadorelin (GnRH) and GMP-certified compounds with personalised cycle design.

Get Protocol

Quick Facts

Molecular weight: 1182 Da
Sequence length: 10 aa
Half-life: ~2-4 min
WADA: Not on prohibited list for males in non-IH context
FDA: Approved for diagnostic LH/FSH testing
Research: Established

Stack Partners

BPC-157

TB-500

Ipamorelin

CJC-1295 without DAC (Mod GRF 1-29)

Semax

Research Note

All protocol / scheduling / cycling applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Gonadorelin (GnRH) unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.

Physician-supervised peptide protocols

Start Your Protocol / Scheduling / Cycling Protocol for Gonadorelin (GnRH)

Alukard provides physician-supervised peptide protocols with GMP-certified compounds with personalised cycle design.

Get a Physician Consultation View All Compounds

HIPAA Compliant · GMP Certified · Physician Supervised